β-Arrestin recruitment assays provide a generic assay platform for drug discovery on G-protein-coupled receptors (GPCRs). The PathHunter™ assay technology developed by DiscoveRx (Fremont, CA) uses enzyme fragment complementation of β-galactosidase to measure receptor-β-arrestin proximity by chemiluminescence. This study describes an agonistic screen on the human endothelial differentiation sphingolipid GPCR 1 (EDG1), also known as S1P1, using PathHunter™ β-arrestin recruitment technology. Screening of a collection of 345,052 compounds yielded 2157 agonistic hits. Only 10 of these compounds showed β-arrestin recruitment activity on a nonrelated receptor, indicating high accuracy and specificity of the assay. The authors show that receptor activation with reference agonists can be detected within the same EDG1 PathHunter™ cell line at the level of β-arrestin recruitment, G i/o protein-mediated inhibition of cyclic adenosine monophosphate (cAMP), and activation of downstream phosphorylation of extracellular signal-regulated protein kinases. The degree of β-arrestin recruitment was largely unaffected upon blockade of G i/o protein signaling with pertussis toxin, whereas kinetic studies demonstrated a lower rate of β-arrestin-receptor association. In contrast, inhibition of cAMP and phosphorylation of extracellular signal-regulated protein kinases were fully G i/o protein regulated. The data indicate that the β-arrestin enzyme fragment complementation cell line can be used not only for agonistic screening of GPCRs but also for the identification of "biased ligands" (i.e., compounds that differ in G-protein coupling and β-arrestin-mediated cellular effects). (Journal of Biomolecular Screening 2008:986-998) 
INTRODUCTION
G -PROTEIN-COUPLED RECEPTORS (GPCRS) are one of the most successful single drug target classes at present, as evidenced by the fact that one fourth of marketed medicines interact with these proteins. 1 Not surprisingly, many pharmaceutical industries continue to actively pursue high-throughput screening (HTS) on large chemical compound libraries to identify new low molecular weight modulators of GPCRs. Traditional cell-based assays for GPCRs take advantage of the functional responses elicited through heterotrimeric guanine nucleotide-binding proteins (G-proteins) following receptor activation, such as the stimulation or inhibition of second-messenger synthesis or gene transcription. 2 Agonist activation of a GPCR leads to the exchange of guanine diphosphate (GDP) for guanine triphosphate (GTP) on the Gα subunit of the heterotrimeric G-protein. The GTP-bound Gα subunit then dissociates from both its neighboring Gβγ subunits and from the receptor. Both the Gα and Gβγ protein subunits interact with intracellular effector proteins, whereas GPCR kinases (GRKs) phosphorylate serine and threonine residues in the intracellular loops and the C-terminal tail of the agonist-occupied receptor. 3 The phosphorylated residues are recognized and bound by β-arrestin, which targets the receptor to clathrin-coated pits for endocytosis. 4 Once internalized, the receptor is dephosphorylated, and agonist dissociates from its receptor due to the acidic interior of the endosomes. The internalized receptor is then either recycled to the plasma membrane or directed to lysosomes for degradation. 5 β-Arrestin not only plays a key role in the attenuation of Gprotein signaling but can also couple GPCRs to members of the Src and mitogen-activated protein kinase (MAPK) families, including extracellular-signal regulated kinases 1 and 2 (ERK1/2). 6, 7 Studies with mutated receptors and ligands, as well as with β-arrestin knockout mice, indicate that G-protein-dependent and β-arrestin-mediated signaling pathways can be separated, raising the opportunity that β-arrestin biased ligands may be developed. 8 Measuring the attenuation of G-protein signaling by β-arrestin and monitoring GPCR internalization are therefore alternative and relatively new approaches for GPCR cellbased assays. 9 Receptor internalization and β-arrestin recruitment have been visualized by creating chimeras with green fluorescent protein (GFP) and using high-content cellular imaging. 9, 10 The approach in which β-arrestin is tagged with GFP is referred to as the TransFluor ® technology. 9 High costs for instruments, licenses, and the complexity of high-content analysis have prohibited broad application of this technology in drug discovery laboratories. Recently, a modified β-galactosidase complementation assay, referred to as PathHunter™ technology, has become available that allows GPCR-β-arrestin proximity to be read on conventional luminometers available in most laboratories. 11 The assay makes use of a unique low-affinity peptide derived from the aminoterminus of Escherichia coli β-galactosidase, which is tethered to the C-terminus of the GPCR of interest, and a ω-deletion mutant of β-galactosidase, which is fused to β-arrestin ( Fig. 1) . The use of the low-affinity peptide, referred to as ProLink™, ensures that the enzyme fragment complementation (EFC) reaction is driven by the ligand-stimulated, reversible interaction of the GPCR with β-arrestin and not by β-galactosidase complementation in the absence of receptor stimulation. 12 The PathHunter™ β-arrestin recruitment assay is a promising new technology but has not yet been validated in HTS. This study describes the agonistic screening of the human endothelial differentiation sphingolipid GPCR 1 (EDG1) using PathHunter™ EFC. EDG1, also known as the S1P 1 receptor, belongs to the lysophospholipid receptor family. Its ligand, the sphingolipid metabolite sphingosine 1-phosphate (S1P), 13 couples exclusively to G i/oproteins, resulting in inhibition of adenylyl cyclase and activation of the MAPK pathway. 14, 15 EDG1 is one of the receptors for the phosphorylated form of fingolimod (FTY720), 16, 17 an anti-inflammatory compound that is currently in phase III clinical trials for multiple sclerosis (The Investigational Drugs database, www.iddb.com, April 2008). The immunomodulatory effect of FTY720 has been attributed to its strong agonistic effect on EDG1 internalization and subsequent excessive degradation of internalized receptors. 18 The resultant decrease in receptor number renders recipient lymphocytes unresponsive to the chemoattractant properties of endogenous S1P. 19 FTY720 acts, in addition to EDG1, on 3 other related S1P receptors, EDG3, EDG6, and EDG8. 16 The preclinical compounds AUY954 20 and SEW2871 21 are EDG1-selective agonists and were used as reference compounds in this study.
The EDG1 PathHunter™ β-arrestin recruitment assay was evaluated in the agonistic format and optimized for HTS, followed by screening of a collection of 345,052 synthetic compounds. Technology artifacts, such as interference with luminescence signal, were de-selected through testing of active compounds on the nonrelated CXCR2 chemokine GPCR, using a PathHunter™ β-arrestin recruitment assay. Hits were confirmed in a cyclic adenosine monophosphate (cAMP) assay measuring activation of G i/o signaling in the same cell line. In addition, the role of G i/o -protein activation on the recruitment of β-arrestin and on the phosphorylation of ERK1/2 was studied.
MATERIALS AND METHODS

PathHunter™ ™ β β-arrestin recruitment assays
The PathHunter™ Chinese hamster ovary (CHO)-K1 EDG1 β-arrestin EFC cell line (catalog number 93-0207C2) and the HEK293 CXCR2 β-arrestin EFC cell line (catalog number FIG. 1. Schematic outline of PathHunter™ enzyme fragment complementation (EFC) β-arrestin recruitment assay. The G-proteincoupled receptor (GPCR) is labeled with a mutationally altered peptide fragment of β-galactosidase (ProLink™ or enzyme donor). β-Arrestin is labeled with a corresponding deletion mutant of β-galactosidase (enzyme acceptor). Recruitment of β-arrestin by the ligand-activated GPCR results in β-galactosidase complementation. The reconstituted holoenzyme catalyzes the hydrolysis of a substrate, which yields a chemiluminescent signal. 93-0202C1) were purchased from DiscoveRx (Fremont, CA). PathHunter™ CHO-K1 EDG1 β-arrestin cells were cultured in Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12) (Invitrogen, Carlsbad, CA) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS; Cambrex, Walkersville, MD), 100 U/mL penicillin G, 100 μg/mL streptomycin, 2 mM L-glutamine, 300 μg/mL hygromycin B, and 800 μg/mL geneticin (all from Invitrogen). PathHunter™ HEK293 CXCR2 β-arrestin cells were grown in DMEM containing 25 mM HEPES and L-glutamine, supplemented with 10% (vol/vol) heat-inactivated FCS, 100 U/mL penicillin G, 100 μg/mL streptomycin, 200 μg/mL hygromycin B, and 800 μg/mL geneticin. Cells were seeded at a density of 10,000 cells per well of a 384-well microplate in 20 μL OPTI-MEM (Invitrogen) and incubated overnight in a humidified atmosphere at 5% CO 2 and 37 °C. The next day, 4 μL of compound solution was added to the cells. Compounds dissolved in DMSO were diluted in phosphate-buffered saline (PBS; HyClone, Logan, UT) containing 0.1% (vol/vol) bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO) to a final concentration of 1 % (vol/vol) DMSO (Sigma-Aldrich), except for the compounds of the screening collection (0.5% DMSO). After incubation for 120 min at 37 °C, the plates were set at room temperature for 60 min. Then, 8 μL per well of PathHunter™ detection reagent (DiscoveRx) was added, and the EFC reaction was carried out for 120 min at room temperature in the dark. Chemiluminescence, indicated as relative luminescence units (RLU), was measured on an EnVision Multilabel reader (PerkinElmer, Boston, MA). To study the role of G i/o -protein activation on recruitment of β-arrestin, cells were pretreated with 100 ng/mL pertussis toxin (PTX; Sigma-Aldrich) for 24 h before addition of agonists. cAMP assays cAMP measurements were performed with a homogeneous time-resolved fluorescence (HTRF ® ) kit from CIS bio international (Gif-sur-Yvette, France). When applicable, cells were incubated with PTX (100 ng/mL) in culture medium for 24 h before performing the cAMP assay. Then, 5 μL of compound or DMSO solution was added to a 10-μL suspension of PathHunter™ CHO-K1 EDG1 β-arrestin cells. Final cell number was 10,000 cells per well in DMEM/F12 supplemented with 100 U/mL penicillin G, 100 μg/mL streptomycin, 1 μg/mL insulin, and 5 μg/mL apo-transferin. Compounds were diluted in Hanks's balanced buffered saline (HBBS) assay buffer (Invitrogen), containing 5 mM HEPES, 0.1% (vol/vol) BSA, 20 μM rolipram (Sigma-Aldrich), and 1 μM forskolin (Sigma-Aldrich), to a final concentration of 1% (vol/vol) DMSO. After incubation for 60 min in a humidified atmosphere at 5% CO 2 and 37 °C, 10 μL of cAMP-XL665 conjugate (1:20 dilution from the HTRF ® kit) and 10 μL of Europium-labeled anti-cAMP antibody conjugate (1:20) in lysis buffer were added. After incubation for 60 min at room temperature in the dark, time-resolved fluorescence was measured at 615 nm and 665 nm on an EnVision Multilabel reader (PerkinElmer). The ratio of the signal at 665 nm and 615 nm was determined for each well of the assay plate.
pERK1/2 assay
Levels of phosphorylated ERK1 and ERK2 (pERK) and total ERK levels were quantitively determined using an ERK1/2 Fast Activated Cell-based ELISA (FACE™) kit from Active Motif ® (Carlsbad, CA). The 96-well white tissue culture plates were coated with 0.1% gelatin (Sigma-Aldrich) in PBS and washed once with 200 μL PBS before 100 μL of cells was seeded at a density of 15,000 cells per well in culture medium. Cells were incubated overnight in a humidified atmosphere at 5% CO 2 and 37 °C. Culture medium was replaced by a 90-μL assay medium (DMEM/F12 supplemented with 100 U/mL penicillin G, 100 μg/mL streptomycin, 1 μg/mL insulin [Diosynth, Oss, the Netherlands], and 5 μg/mL apo-transferin [Sigma-Aldrich]) and incubated overnight in a humidified atmosphere at 5% CO 2 and 37 °C. When applicable, culture medium was replaced by a 90-μL assay medium containing 100 ng/mL PTX.
The next day, 10 μL of compound solution was added to the cells. Compounds were diluted in PBS containing 0.1% (vol/vol) BSA to a final concentration of 1% (vol/vol) DMSO. Cells were treated for 5 min with agonists at 37 °C. Cells were fixed by replacing the assay medium with 100 μL of 4% formaldehyde (Bio-Connect, Huissen, the Netherlands) in PBS. After a 20-min incubation at room temperature, cells were washed 3 times with 200 μL wash buffer (0.1% [vol/vol] Triton X-100 in PBS from the FACE™ kit) followed by an incubation of 20 min with 100 μL quenching buffer, containing 1% (vol/vol) hydrogen peroxide (Thermo Fisher Scientific, Waltham, MA) and 0.1% (vol/vol) sodium azide (Sigma-Aldrich) in PBS. Cells were washed 2 times with wash buffer, incubated for 1 h with 100 μL antibody blocking buffer from the kit, and washed 2 times again. Then, 40 μL of diluted antibody against phosphorylated ERK1/2 (1:500 from the FACE™ kit) was added and incubated overnight at 4 °C. The phospho-ERK antibody has been raised against a synthetic phosphopeptide corresponding to residues Thr202 and Tyr204 of human ERK1 and Thr185 and Tyr187 of human ERK2. For the detection of total ERK, antibody against ERK1 and ERK2 (1:500 from the FACE™ kit) was added. The excessive primary antibody was washed out, and 100 μL of diluted horseradish peroxidase (HRP)-conjugated antirabbit IgG (1:2000 from the FACE™ kit) was added and incubated for 1 h at room temperature. Secondary antibody was removed and cells were washed 3 times with wash buffer and twice with PBS. Then, 100 μL per well of FACE™ chemiluminescent working solution was added. Chemiluminescence was measured on an EnVision Multilabel reader. van der Lee et al.
Data analysis
On every 384-well assay plate, 16 wells were used as "minimum effect" wells and 16 wells as "maximum effect" wells. On a 96-well assay plate, 8 wells were used for both the minimum and maximum effects. The effect of the compounds was calculated as a percentage of the maximum assay signal with the mean minimum and maximum values of the control wells obtained from the same plate set at 0% and 100%. Assay quality was monitored by calculation of the Zhang prime (Z′) factor. 22 Curves were fit by nonlinear regression using the sigmoidal dose-response equation in GraphPad Prism Version 4.03 (GraphPad, San Diego, CA). t 1/2 values were calculated by One Phase Exponential Association analysis in GraphPad Prism. All graphs and data points shown are mean values ± SEM obtained from at least 2 independent experiments performed in duplicate.
RESULTS
HTS and hit confirmation
The PathHunter™ CHO β-arrestin EFC cell line expressing EDG1-ProLink™ was validated with the selective and full EDG1 reference agonists AUY954 20 and SEW2871. 21 The low nanomolar EC 50 s of AUY954 (2.6 nM) and SEW2871 (9.5 nM) ( Table 1; Fig. 2 ) corresponded well with the activities reported in literature for GTPγS functional assays (1.2 nM and 13.8 nM, respectively). 20, 21 Various experimental conditions were tested to evaluate the assay for HTS. Differences in cell density between 2500 and 10,000 cells per well and DMSO concentrations up to 1.0% (vol/vol) did not affect the signal-to-background (S/B) ratio and potencies of the reference agonists (data not shown). At 1.5% DMSO, both the maximum and minimum signal increased, whereas the S/B ratio remained the same as well as the potency of the reference agonists. When the incubation time with compound was increased from 1 to 2 h, a slightly higher S/B ratio and an increased potency for both SEW2871 and AUY954 were observed ( Fig. 2A, B) . The luminescent signal reached a plateau at a 60-min incubation time with detection reagent and remained stable for at least another hour. All reagents used in the assay, including the cells, were stable up to 24 h, facilitating the screening of large compound libraries.
A collection of 345,052 low molecular weight synthetic chemicals was screened at a concentration of 10 μM in 0.5% DMSO on an automated system. A typical screening day of 120 plates revealed a stable maximum and minimum signal over time with an S/B ratio for AUY954 between 3 and 5 and an average Z′ of 0.54 ( Fig. 3) . Assay plates with a Z′ < 0.4 were rejected and retested. Actives were selected with more than 99% confidence outside the mean minimum effect based on the activity criterion (i.e., >20%) given in Figure 4 . These compounds were retested from the same DMSO stock, resulting in 2157 active compounds in 2 separate assays.
To de-select technology artifacts, we tested all 2157 active compounds in the DiscoveRx HEK293 β-arrestin EFC assay for the G i/o -coupled chemokine receptor CXCR2 (Fig. 5) . The cells for this assay were thawed either from cryopreserved "frozen" cell stocks in microplates provided by DiscoveRx or from vials produced in-house from the same cell stock stored at -140 °C. Comparison of agonistic and antagonistic dose-response curves revealed no differences between CXCR2 PathHunter™ cells that had been maintained in culture and seeded in microplates the day before the assay ( Fig. 5A ) and cells that had been delivered frozen in microplates by the supplier (Fig. 5B) . Standard cryopreservation 23 and direct assaying did not work for as yet unknown reasons for the EDG1 cell line (data not shown). This cell line was always cultured for at least 2 passages before an assay was performed.
Only 10 compounds identified in the EDG1 screen showed more than 20% agonistic activity in the CXCR2 assay. This suggests that the remaining 2147 compounds interacted selectively with EDG1. These compounds were divided in different groups based on similarities in chemical structure, so-called clusters. Fresh samples of 72 compounds representative for the different clusters were dissolved in DMSO and tested in parallel in the EDG1 β-arrestin recruitment assay and in a cAMP assay performed in the same cell line. In this assay, cAMP level was increased by costimulation of the cells with 1 μM forskolin. cAMP in cell lysates was measured using an HTRF ® assay. Activation of the Gα i -coupled EDG1 results in a decrease in forskolin-induced cAMP accumulation. Sixty-seven compounds were found to be active in both the β-arrestin and the cAMP assays. One compound was only active in the cAMP assay (43% effect at 1.0 μM), and another compound was only active in the β-arrestin assay (24% effect at 1.6 μM). The tested compound concentrations were not identical in the cAMP and β-arrestin assays due to differences in the DMSO tolerance. In the cAMP assay, the highest acceptable DMSO content was 0.1% (vol/vol) instead of the 1% (vol/vol) used in the EFC assay. Three compounds did not show any activity in either of the 2 assays, most likely because the compounds were tested at a lower concentration than in the screen (i.e., 10 μM). The compounds had no effect on cAMP levels in the parental CHO PathHunter™ cell line, which expresses endogenous sphingolipid receptors but lacks overexpression of EDG1 (data not shown). The majority of the 67 compounds that were active in both assays (Fig. 6A) showed a stronger effect in the cAMP assay, even though the compounds were tested in this assay at a 1.6-times lower concentration (i.e., at 1 μM) in comparison to the β-arrestin assay. However, the correlation between the percentage effect of the compounds obtained in the 2 assays was poor, as indicated by the variation coefficient, R 2 , which was 0.57. In addition to being more efficacious, compounds were also more potent in the EDG1 cAMP assay. Dose-response curve analysis of 3 hits revealed potency difference of 0.5 to 0.7 log units ( Fig. 6B-D; Table 1 ). A shift in potency was also found for the reference agonists AUY954 and SEW2871, which were, respectively, 1.47 and 1.06 log units more potent in the cAMP assay ( Table 1) .
Contribution of G-protein signaling to β β-arrestin recruitment
According to the current model, G-protein activation precedes and is required for the activation of GRKs, which phosphorylate the receptor and thus create a high-affinity binding site for β-arrestin molecules. 3, 24 However, G-protein-independent cellular effects of GPCRs that are insensitive to inhibitors or modulators of G-protein function have been reported. 25 To study the role of G i/o -protein activation on the recruitment of β-arrestin, we carried out experiments with PTX. PTX catalyzes the adenosine diphosphate (ADP)-ribosylation of Gα i and Gα o proteins, preventing their binding to activated receptors. 26 EDG1 cells were treated with 100 ng/mL PTX for 24 h, before addition of agonists. PTX treatment decreased forskolin-stimulated cAMP accumulation by 35% to 40% (Fig. 7A, C) , as has been described
FIG. 2. Dose-response curves for endothelial differentiation sphingolipid GPCR 1 (EDG1) receptor agonists (A) AUY954 and (B) SEW2871
in enzyme fragment complementation (EFC) β-arrestin recruitment assay at 30 ( ), 60 ( ) and 120 ( ) min incubation time and vehicle only signal (◊). Average pEC 50 values ± SEM and efficacies (in brackets) of AUY954 were 8.01 ± 0.03 (98%) ( ), 8.19 ± 0.03 (100%) ( ), and 8.34 ± 0.03 (107%) ( ), respectively. Average pEC 50 values ± SEM and efficacies (in brackets) of SEW2871 were 7.73 ± 0.03 (100%) ( ), 7.96 ± 0.03 (108%) ( ), and 8.05 ± 0.03 (123%) ( ), respectively. Efficacy at 60 min was arbitrarily set at 100%. Chemiluminescence was indicated as relative luminescence units (RLU). Representative graphs from 2 independent experiments performed in duplicate with mean values ± SEM are shown.
FIG. 3.
Typical performance of a screening day of the endothelial differentiation sphingolipid GPCR 1 (EDG1) enzyme fragment complementation (EFC) β-arrestin recruitment assay. Plate 27 was rejected due to failure of detection reagent addition. Maximum ( ) and minimum ( ) values and signal-to-basal (S/B) ratio ( ) for AUY954 are represented for a high-throughput screening run of one hundred twenty 384-well plates. Wells containing 1 μM AUY954 were used to determine the maximum signal, and wells containing medium plus 0.5% DMSO without compound were used to determine the minimum signal. The average Z′ factor was 0.54. RLU, relative luminescence units. before in HEK293 cells. 27 Nevertheless, the inhibitory effect of the compounds on intracellular cAMP levels was completely blocked by PTX ( Fig. 7A, C) . In contrast, the effects on β-arrestin recruitment were largely maintained (Fig. 7B, D) . PTX pretreatment resulted in a 0.53 and 0.65 log unit decrease of the potencies of AUY954 and SEW2871, respectively ( Fig. 7B, D; Table 1 ). The efficacies of the 2 compounds were slightly increased, that is, to 128% for AUY954 and to 111% for SEW2871 ( Fig. 7B, D; Table 1 ).
To evaluate the role of G i/o -protein coupling/activation on β-arrestin recruitment kinetics, we analyzed β-arrestin recruitment in time during receptor activation with AUY954 or SEW2871 in PTX-treated and control EDG1 cells (Fig. 8A, B) . Maximal response was obtained after 10 to 20 min of incubation with agonist in control EDG1 cells. The corresponding half times (t 1/2 ) for AUY954 and SEW2871 were, respectively, 2.6 and 1.9 min. In contrast, a 6-to 8-times slower rate of β-arrestin recruitment was found in the PTX-treated EDG1 cells. These data suggest that G i/o -protein mediated coupling/ activation regulates mainly the rate and, to a lesser extent, the number of β-arrestin molecules recruited.
Contribution of G-protein signaling to ERK phosphorylation
β-Arrestin has been shown to link GPCR activation to protein kinase signal transduction for some certain receptors. 6 To evaluate the role of Gα i/o -protein activation on EDG1-stimulated phosphorylation of ERK1/2, cells were treated overnight with 100 ng/mL PTX, prior to incubation with agonist. Phosphorylation and total levels of ERK1/2 were measured in the pERK1/2 FACE™ assay. AUY954 and SEW2871 induced ERK1/2 phosphorylation in a concentration-dependent manner, after 5 min of stimulation (Fig. 9A, B) . The compounds had no effect on total ERK protein levels (data not shown). The potencies of AUY954 and SEW2871 in the pERK assay were similar to the activities measured in the β-arrestin assay ( Table 1) . Preincubation of the EDG1 PathHunter™ cells with PTX almost completely abolished ERK1/2 phosphorylation in response to 100 nM AUY954 or 1 μM SEW2871 (Fig. 9A,B) . This indicates that EDG1 activation to ERK signaling occurs primarily through activation of G i/o -proteins at early time points. A characteristic property for β-arrestin-dependent ERK activation is a more prolonged duration in comparison to G-protein-mediated ERK activation. However, even prolongation of the agonist incubation time up to 60 min in PTX-treated cells did not result in significant ERK1/2 phosphorylation (data not shown). These data indicate that ERK activation depends on G-protein activation also at a later time point of 60 min.
DISCUSSION
The availability of low-affinity complementing peptides derived from the amino-terminus of β-galactosidase has enabled the development of EFC assays that allow reliable quantification of the interaction of 2 proteins expressed within the same cellular compartment. 12 The application of this technology to measure GPCR-β-arrestin interaction has resulted in a simple highthroughput assay for drug screening and de-orphanization. We have evaluated this new EFC technology for screening of agonists of the S1P receptor EDG1 and found that the assay was robust and highly accurate, as judged by the low percentage of false positives of 0.5%. This number compares favorably with the classical agonistic GPCR HTS assays. For luciferase reporter gene assays, we find that usually 30% to 40% of the confirmed actives from HTS are false positives in counterscreens with parental cell lines that do not express the GPCR of interest. In the case of antagonistic luciferase screens, the number of false positives is even higher. 28, 29 A possible explanation for the favorable result obtained with the EFC technology is that β-arrestin recruitment is read close to the receptor and that assay signal requires only the activation of the receptor. Another advantage of β-arrestin EFC is the use of tagged receptors. This enhances the specificity of the signal, particularly when a cell line is used expressing endogenous receptors that respond to the same ligands. Several S1P receptors, including EDG1, are endogenously expressed in CHO-K1 cells. 27, 30 This did not affect the results from the cAMP assay, as the reference agonists and the hits from HTS were not active on the EFC parental cell line. A possible disadvantage of and (B, D) enzyme fragment complementation (EFC) β-arrestin recruitment assay, in the absence ( ) and presence ( ) of pertussis toxin (PTX). Cells were pretreated for 24 h with 100 ng/mL PTX, prior to stimulation with reference agonists. PTX had no influence on the vehicle control (◊). In the cAMP assay, 1 μM forskolin was used to induce adenylyl cyclase in parallel to agonist stimulation in cells pretreated with PTX ( ) and nontreated cells ( ). Representative graphs from PathHunter™ EFC is that receptor tagging may result in perturbation of proper receptor function. However, this does not seem to have occurred in the EDG1 PathHunter™ cell line, as the pharmacology of the 2 EDG1 reference compounds was maintained in the pERK assay and in agreement with reported activities in GTPγS functional assays. 20, 21 The agonistic activity of interleukin-8 (IL-8) in the CXCR2 PathHunter™ assay was also similar to the reported binding affinity. 31 Sixty-seven of the 68 compounds (99%) identified with the β-arrestin recruitment assay were also active in a cAMP assay measuring signaling via G i/o -protein in the same cell line. When measuring the agonist activation of G i/o -coupled receptors, forskolin is commonly used to activate adenylyl cyclase because the agonists usually do not have a measurable effect on basal levels of cAMP. Priming of cAMP with forskolin increases assay variation due to variation in the forskolin response of cells. For this reason, β-arrestin EFC may be in particular suitable as an alternative assay format to screen for agonists of G i/o -coupled receptors. It should be noted, however, that the hits from HTS were slightly more potent in the cAMP assay than in the β-arrestin recruitment assay. Moreover, the reference agonists were up to 1.5 log units more potent in the cAMP assay than in the β-arrestin recruitment assay. Adjustments of the cAMP procedure to the EFC assay, such as prolonging the agonist incubation time and using similar assay medium, did not affect the compound activities (data not shown). On the other hand, inhibition of cAMP accumulation at an increased forskolin concentration of 10 μM instead of 1 μM decreased the potency of AUY954 from 0.09 nM to 1 nM, respectively (data not shown). Still, the lower potency (EC 50 ) in the cAMP assay suggests signal amplification in this assay, as the EC 50 s in the β-arrestin recruitment assay were similar to those in the ERK phosphorylation assay and literature GTPγS binding. ERK phosphorylation and cAMP are both Gα i/o -protein dependent, as demonstrated in experiments with PTX treatment of cells. We conclude from the minor effects of PTX on EFC that β-arrestin recruitment in the PathHunter™ EFC cell line occurs primarily through a G i/o -protein-independent mechanism. Although in vitro experiments with reconstituted receptor-Gprotein complexes have demonstrated that EDG1 couples exclusively to G i/o , 15 we cannot exclude that other G-proteins take over in the PTX experiments. However, Gα s -protein does not seem to play a role, as there was no increase in intracellular cAMP after PTX treatment ( Fig. 7A, C) .
PTX caused small decreases of the potencies of AUY954 and SEW2871 in the β-arrestin EFC assay and slight increases of their efficacies (Fig. 7B, D; Table 1 ). Kinetic studies showed that PTX reduced the rate of EDG1 β-arrestin recruitment induced by AUY954 and SEW2871 (Fig. 8A, B ). An effect of PTX treatment on the rate of receptor internalization has previously been shown for the M4 muscarinic acetylcholine receptor. 32 The PTX data suggest that the interaction of EDG1 with β-arrestin was changed. Most likely this change reflects a difference in phosphorylation or even a lack of phosphorylation of the receptor after ligand binding. It is generally known that Gprotein activation results in the activation and recruitment of GRKs or other serine/threonine protein kinases (protein kinase A [PKA] or protein kinase C [PKC]) that phosphorylate the receptor. 3 Because the negatively charged phosphorylated receptor binds β-arrestins with high affinity, and as β-arrestin undergoes conformational changes after binding, it is likely that different patterns of receptor phosphorylation sites can affect its interaction with β-arrestin as well as the conformation of the β-arrestin molecule itself.
In the case of EDG1, it has been demonstrated that GRK2 and PKC target a conserved serine-rich region in the C-terminal tail of the receptor for phosphorylation. 18, 33 Furthermore, a threonine residue in the third intracellular loop is phosphorylated by protein kinase B (PKB). 34 On one hand, PTX might block the activation and recruitment of PKC and PKB, as well as GRKs 2 and 3, because these kinases critically depend on the interaction with heterotrimeric Gproteins and phosphatidylinositol 4,5-biphosphate. 3 On the other hand, prevention of G i/o -protein activation by PTX might favor recruitment of GRK subtypes 4, 5, and 6, as these GRKs are constitutively associated with the plasma membrane and thus could directly phosphorylate the receptor. 3 β-Arrestin binding and its affinity for EDG1 could also simply depend on the number of receptor-attached phosphates as observed for rhodopsin and other GPCRs. 35, 36 For the leukotriene B4 receptor 1 (BLT1) 37 and the β 2adrenergic receptor (β 2 AR), 38 it was shown that β-arrestin can even associate to an unphosphorylated receptor. In conclusion, PTX treatment may have resulted in a decreased coupling efficiency of the ligand-bound receptor to β-arrestin due to decreased phosphorylation of the receptor by GRK, PKC, and/or PKB. This ultimately may have resulted in a decreased potency of the reference compounds in the presence of PTX in the EFC assay.
A different explanation for the changes in pharmacologies is that PTX could have altered the expression or function of other pathway elements involved in the EFC cells. We note that the minor effects of PTX on EDG1 β-arrestin recruitment are in agreement with data obtained for engineered mutants of the platelet-activating factor receptor (PAFR) and the angiotensin II receptor type 1 (AT1) receptors that are incapable of coupling to G-proteins. 39, 40 In line with this, other G i/o -coupled receptors, including cannabinoid receptor 1 (CB1) 41 and the chemokine receptor CXCR3, 42 have been shown to internalize while cells were PTX treated.
β-Arrestin not only plays a role in the attenuation of G-protein signaling but also can function as a signal transducer by coupling GPCRs to particular protein kinase pathways. 6 Because the EDG1 receptor is exclusively coupled to G i/o , activation of ERK/MAPK will probably occur in a Gβγ-dependent manner through PI3K and Ras. 43 We examined the role of G i/o -protein activation on EDG1mediated phosphorylation of ERK1 and ERK2 by PTX treatment of EDG1 PathHunter™ cells. Although β-arrestin recruitment was largely unaffected by PTX, the phosphorylation of ERK1 and ERK2 was fully blocked by PTX for SEW2871 ( Fig. 9B) and largely inhibited for AUY954 ( Fig. 9A) . In general, the EDG1mediated G-protein dependency in ERK1 and ERK2 phosphorylation is in agreement with previously published PTX studies. 21, 44 Recent evidence demonstrates that certain agonists can selectively activate β-arrestin signaling without stimulating G-proteins. This phenomenon is referred to as biased agonism or ligand-directed signaling. 8 One example is carvedilol, a nonselective βAR antagonist indicated in the treatment of heart failure. 45 Carvedilol promotes β-arrestin-mediated signaling and antagonizes G-protein activation. 46, 47 Another example is SII angiotensin, a mutationally altered derivative of the peptide ligand angiotensin. SII angiotensin is unable to induce Gα q -mediated mobilization of second messengers but still is able to activate βarrestin-dependent signaling to ERK. 48 The existence of biased ligands opens new opportunities for the development of pathway-specific drugs with valuable therapeutic properties. We were able to detect β-arrestin recruitment, G i/o -protein mediated inhibition of cAMP, and downstream phosphorylation of ERK within the same EDG1 EFC cell line. This is the first study in which agonist potencies have been assessed on these 3 signaling events within 1 EFC cell line. The PathHunter™ β-arrestin EFC cell line is also unique in the sense that compound libraries can be screened within 1 cell line for the identification of compounds that differ in G-protein coupling (cAMP) and β-arrestinmediated (EFC) cellular effects. This opens up new avenues for the identification of small molecules that differentially modulate these processes.
